PARSIPPANY, N.J.--(BUSINESS WIRE)--$MDCO #infectiousdisease--The Medicines Company (NASDAQ:MDCO) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the investigational agent CARBAVANCE® (meropenem-vaborbactam) for the treatment of complicated urinary tract infections (cUTI). CARBAVANCE is the combination of the carbapenem antibiotic, meropenem, with the novel beta-lactamase inhibitor, vaborbactam (formerly known as RPX7009), that is being developed for the treatment of
![]()
↧